Cambridge Cognition Holdings Plc engages in the development and marketing of digital solutions to assess brain health. Its products include CANTAB, Electronic Clinical Outcomes Assessment (eCOA), NeuroVocalix, Winterlight, Cognition Kit, Clinpal, eConsent, and AQUA. CANTAB Connect gives the control to manage and deliver battery of touchscreen and voice assessments, as well as fully customizable electronic questionnaires and scales. The Company’s therapeutic areas include attention deficit hyperactivity disorder (ADHD), Alzheimer’s Disease, Autism Spectrum Disorder, Cognitive Safety, Core Cognitive Function, Depression, Down’s Syndrome, Drug Abuse Liability, Epilepsy, Huntington’s Disease, Multiple Sclerosis, Neuromuscular Disorders, Obsessive Compulsive Disorder, Parkinson’s Disease, Schizophrenia, Stroke and Cerebrovascular Disease, and Traumatic Brain Injury.